Recent articles
2 Breast Cancer Fighting Stocks to Invest In
Promising new results in breast cancer will be presented at next week's San Antonio Breast Cancer Symposium. Here's what to look for.
Save Yourself the Migraine and Buy This 1 Pharma Stock Now
Late-stage clinical trial results provide a chance for investors to gain significant upside from this developer of drugs combating neurological diseases.
Better Buy: Editas Medicine or Sangamo Therapeutics?
These gene-editing trailblazers continue advancing exciting new approaches to treating inherited diseases.
2 Small-Cap Biotechs That Soared Last Week
New drugs from these companies seek to enable more patients to receive cutting-edge cell and gene therapies.
Global Blood Therapeutics Goes Head to Head With Novartis On Sickle Cell
Transformative new therapies are changing the treatment landscape for patients with sickle cell disease, and savvy investors can benefit in this David-versus-Goliath scenario. Which one is the better buy today?
Will Thermo Fisher Buy Qiagen?
Shares of the Dutch diagnostic test manufacturer Qiagen popped after it confirmed ongoing buyout discussions with Thermo Fisher Scientific and others.
1 Attractive Pharma Stock You Probably Haven't Heard Of
This global pharmaceutical company has a healthy dividend and a bevy of new drugs set to enter the market in the coming years.
Is Exact Sciences Stock a Buy?
Exact Sciences just completed its multibillion-dollar acquisition of Genomic Health, setting the stage for the company’s future.
BDCs: 4 High-Dividend Ideas to Boost Your Portfolio
Wish you could invest in private equity? Business development companies provide a unique, high-yield avenue that lets you co-invest with the titans of Wall Street.
Exelixis’ Stock Regains Its Mojo
Snapping a downward trend since spring, recent developments have breathed new life into Exelixis’ stock.
Is Medtronic a Great Dividend Stock?
Medtronic touts an admirable run of increasing its dividend over 42 consecutive years. But, is the dividend enough for investors to get excited today?
Here’s Why FibroGen’s Stock Popped Friday
FibroGen reported highly anticipated clinical data on Friday for its lead drug roxadustat in chronic kidney disease.
Better Buy: Intercept Pharmaceuticals or Genfit?
Both companies aim to grab a piece of the multi-billion dollar market for treating patients with the liver disease NASH. So, which one should you buy?
2 Biotech Stocks Fighting Alzheimer’s Disease to Own Now
No new drugs have been approved for Alzheimer’s disease since 2003. However, new approaches may soon bring options for the 5.7 million Americans suffering from the disease.
Is Corbus Pharmaceuticals Stock a Buy?
It’s full steam ahead with a slate of late-stage clinical trial results expected in 2020. However, Corbus just release its third quarter results, and the financial picture looks bleak.
These 3 European Biotechs Can Help Recession-Proof Your Portfolio
Biotechs trade on the prospects of new advancements to identify and treat diseases. That's something the world needs in good times and bad.
Buy These 2 Stocks to Access China's Huge Healthcare Market
BeiGene and Zai Lab offer two ways to invest in what could be a big opportunity.
4 Stocks Battling Breast Cancer
With Breast Cancer Awareness Month drawing to a close and the San Antonio Breast Cancer Symposium on the horizon, stay alert for breaking news from companies developing new treatments.
Is This Small-Cap Biotech a Buy Before 2020?
Stocks of drug developers, particularly small ones, can skyrocket or crater based on late-stage clinical trials. Before year-end, ChemoCentryx may do one or the other.
3 Things to Watch From the Pharmaceutical Industry's Liver Meeting
Investors will want to pay attention to what Assembly Biosciences, CymaBay Therapeutics, and Madrigal Pharmaceuticals say about their most promising candidate therapies.